Mavacamten has been approved for adults with hypertrophic cardiomyopathy since 2022, but hadn’t yet been tested in adolescents or children.
Mavacamten has been approved for adults with hypertrophic cardiomyopathy since 2022, but hadn’t yet been tested in adolescents or children.A once-daily pill could change how doctors treat teens with hypertrophic cardiomyopathy, a genetic heart condition that can block blood flow, a Philadelphia researcher has found.
Children’s Hospital of Philadelphia cardiologist Joseph Rossano led an international trial involving 44 patients ages 12 to 17 that studied a drug already approved for adults with the condition. His work showed the drug, mavacamten, could also significantly reduce blockages in youth — and possibly delay the need for surgery.a common inherited heart disease The condition causes the heart muscle to thicken, which can obstruct blood flow. In such cases, the heart is strained as it works harder to pump blood out to the body. Over time, the condition can lead to heart failure, abnormal heart rhythms, and“This can present at any age, and sometimes the first symptoms could be the last symptom,” Rossano said. Mavacamten has been approved for adults with the condition since 2022, but hadn’t yet been tested in adolescents or children. . Participants did not know whether they received the intervention or not, a study design that’s considered the gold standard for medical research. They were followed for 28 weeks. The researchers compared the amount of obstruction before and after, evaluating levels of pressure in an area of the heart where healthy levels would be around 0 mmHg and above 30 mmHg would indicate an obstruction. The mean levels before treatment in both groups were around 80 mmHg. By the end of the trial period, the teens receiving mavacamten saw these levels cut substantially with an average drop of 48 mmHg, compared to 0.5 mmHg in the group receiving no drug. “Nothing else can do that besides surgery,” said Elizabeth Blume, a pediatric cardiologist and professor of pediatrics at Harvard Medical School who was not involved with the study or the pharmaceutical company. Some of the children would have needed a myectomy, a surgery where doctors remove muscle that’s blocking blood flow, she said. It’s the primary treatment for young patients with severe obstruction, when medication fails to relieve symptoms. But the effects of the drug were significant enough that they might not need surgery, at least for the time being. “Imagine being the parent of a 12-year-old who can now take a medicine by mouth rather than have open heart surgery,” said Blume, who also leads the advanced cardiac therapies divisionalthough he wasn’t sure whether it could be avoided altogether .His team found that the heart was able to relax better on the drug. The heart also becomes less thick. And when the researchers looked at markers of injury in the heart, they found those in the mavacamten group showed decreased levels. Those in the placebo group had slightly increased levels. These early findings suggested to Rossano that the drug might improve the way patients’ hearts function in the long-term. If these effects are confirmed in a longer-term trial, doctors may want to start patients on the drug at an early age to avoid heart damage that could otherwise accumulate over time. “If we identify patients young with this and get started on medicines early, their hearts could be much better, 10, 20, 30 years later than if they weren’t started on the medicine,” he said. He noted a limitation of the trial was its relatively small sample size. Longer-term studies are being planned.groups, with two patients in each having a serious event. In the mavacamten group, one teen experienced two fainting episodes, while another had an inappropriate shock delivered by an implantable cardioverter defibrillator .Blume called the rate of serious adverse events low for a group of sick pediatric patients. To her, there didn’t appear to be any “surprises” compared to the adult trial.FDA-required warning on its box for risk of heart failure. This rare but serious risk of the drug requires regular monitoring through echocardiograms. Going forward, Blume also wanted to see long-term outcomes, since the study period of 28 weeks is a “very short time,” she said. The potential effects of puberty, for example, should be monitored in followups of multiyear outcomes. She would also want to see a study in youngerBlume applauded the investment of time and resources needed to figure out if there are differences in dosing and side effects for children compared to adults, describing it as a “rarity.”{"ENV":"fFl/Q10cXQZ/TWtHdzF8A39jZE93DHNZfHBoCg==","CONTENT_BASE_PROD":"aF13TXcxWQBTBF1ZYzFwA3xwfAZ3InBNfGB4BmMicAZ8YHRAdjJzWHxwZE92InBCfGBrWnccZAdrYHhAYAxgAHxzaE9gHGNZf2BrW3dUfAB8c1pAdiJ/WHxdfE5jC2Nea11VWnQxY10=","ARC_ACCESS_TOKEN_PROD":"UgRzA11VYwVoYHxNWwxaQn9jdAJ0IWxCfE1ST3ciUkx+c3QDdzFkQnxNc1x0InwEa2NgA3QiZEx8TXgGdBxgBGtaa110HHRMfnN0BnQiVk1rXXwDYzJSTH9dVV90VGBNa2BrXXQxbE1/BWQFdCJkTGhgZAZ3Il1Za2N3W3QibE1+YGgFdBxgTX8FZAd0Mmdcf2NwBHQhbE1/c3xOdCFwQmtjd11jMW9YfwV4BGMyf1lrWmROYzF/WGhdcE10IW9Za3BkQHcMXk1/WmtcYzJ0CA==","GRAPHQL_KEY":"aGB/TXQhAE1rcEUHdAxSA3xdfE9gMngEf1poBHYxbAR8BXxPYyJ7XX8FeEB0HHtff3N7WnQMbAFrYGROYDJzXmtgaEB3IlFff2N8QGAMd1xrXXQGdFRvWHxzdAZ0C2NdfGBoBmM3CAg=","GATEWAY_URL":"UgV7XFw+XVh+YEFBdwh8A39gaEB3MnddfGNwQHcyc19/Y3BPdCJzXmhddEBjMnQEfF1WBnQMdAd8cGBPYFR8BHxgZAZ0C39dfF1zWnYhY11rYHtbdDFvXg==","GATEWAY_SLS_URL":"UFpBWncxbE1Vf3RNWDEFA39zaEBjInQBf2B8T2AMZ1x8YGBAYAxkTWtgZE90MnNffF1wBnQiZ118Y3wHYAtsAXxzZEBjMWAEfAVrW3QxYExrY11fYyFgTw==","FEEDS_URL":"a2BVAXQiY15oTWdfdC5sA39zXVt3HHBMf2BkB3Yic198cGAHdCJwAX9zaEB3HHNZfF18QHQMZE98cHhPdyFjX2hdc1t3HGxCfF1kT2AxY1x8c1IFdzF8TWtjZE5gHFZCfF1oBWAxYAdrXV1aYzFjWX9jfAo=","RESIZER_KEY":"fFoAAlghTUN/cEYHdwhwA3xzaE53DHRNfHB0BXciYAR/WmhNYBxRXH9jcE9gMm9dfGB8TmAMYAZrYGBAdyF8AHxdYAd3DH9ea11oBHYic1hrXXBNYDFvX2taYAR2IWAEaFpgBnQnCAg=","GOOGLEANALYTICS_ID":"f01gB2M+YAVTf3NaWi5SA3xzeE90HHdffF1kT2MydE9/Y3AHYzJjX39gaE13Im9f","TWITTER_API_TOKEN":"a2NZBnQhUgdUcEYGdz5sA3wFaARgDHwBf11WQHRUfAR8YGBAdzJRX39jfE53C2AEf01WTXcyb1hrY1YHYwx8B2tgaAdgDFFcfE1zW3YxfAZ8Y1IHYzJ8B2hjaAZ2MndYaFpgBmMLbE9rYHQFdCFsTGhdXVp0MX9cfGN/W2MiXgVoYGROYyJ3Xn9zc1p3IXNda2NdXmAMdE18c2QCdFRzX2tzY110ImdcaE1VXmMxYAR/cH9adDF4QmhgYAN3IWRCa1pkAnYhZ15oWndaYyFwTHxzd1p3C3Ndf3B4QGMLZAF+YH9bYwtwTGtdf190C2NYfHNrX3QMUkxrYHtfdAtwBmtza19jDHNdfmNnXGMhbE9+Y1ICYzFkTGhNeAd0C2dZfmBjXWMMWV9oBXtddCJZXWhdVV13MWRCfmNSCg==","GOOGLE_CLIENT_EMAIL":"a11/A2M+UgZSWghCXRxaQn5zZAV0MXAFaF1nWncyXkJoXXdfdCJsQn9dc193MlJPfnN3W3Qib1x/Y3AHYzJsTX5zYAJ0DFIFfnBrXHQMeE98Y2gGdBxSTH9wZAZ0DGRMa1p4A2MMZ1l8cGdeYDFgT39aZANjMnRNa1pkA2Ayf1loBWtedAxZXH5wYE90HGdYf3BjXmMMfAd+c3hAYBxjXnxADAo=","GOOGLE_PRIVATE_KEY":"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","BLUECONIC_ENDPOINT":"U2NwBHQ+ewZ/b2teYAtaA3xgdAZjDGABfGBoB2AMdAV/YHhAdBx3XXxjZ1tgMnAAf010QHQxfE98c3NadwxkB2taZ1t3Mn9Ya2NaBnQMVgR/XWtfdCFvWWtaeEBgMW9d","BLUECONIC_STORE_ID":"VU1aT3YicwRSWXMGdAtSA3xjaAZ3DGBMfHBgBncieAd/c2BPYzJnWH9zYAZ3MnABaFpoBHQiUV1/TXhAdyJkBHxzeEB3DGQFfF1wTXcMVgV/BWQFdjJsBXxNaEBgHH9ffAV0BXQieAFrXVledDJsBQ==","BLUECONIC_KEY":"fm9jA3QLZ0NSYABZWwhwA39zVk9gDHdcf2BgB3QMcAV8YGhAdAEICA==","BLUECONIC_SECRET":"U29BA1oLbAZVXXwDWwxeA3xNWk5gMntdfHNkQHQcZE98c3xAdiJvWXxjYAR3MWNff2NoTmMyfEx8c3gHYFRvWH9NZAdgMnAHaF17WmMLbAZ8XWBOdFRgTH8FdAZ3ImBCaF18QHY3CAg=","AMP_AUTH_BASE_URL":"U2N/X3YuRUVSXVYFYwteA3xza150HHAAf2BoQHcicAR8c3wGYwx0THxwd1t2InAHf010BncLf198c3RPYAxkBmhdVgdgDH9Zf2NVW3ccZAFrY1YHdFRjXWtjaE53VHxPf01zWnRUY15rYGdfdwtgB2hjYE13HHdca2B7X3QcWVloTVVadDcICA==","AUTH0_DOMAIN":"UnAITV0yZAV/f14GWwxaTWtjc190MnAEaF13XHcyeAVrY3QGdyF/WWtzcAR0Ml1Yf11wTXciXgV8Y2ADdCJ8CA==","AUTH0_CLIENTID":"U3N4A1w+UUVrBFVadjENA3xzYAd2IndefFpgT3Qie1h8c1oHdiFgBH9dVkBjMndffGNkQHccZAd8WmNbdCJ0BnxjcE12MnRCfHBgTmALfARoWnRAYzJ8BmtgZAZ2MnQHfHNwB2ARCAg=","PIANO_ID":"U1p3T3QieAZUb2dYdjJaTGhNcAV0HHwEfHNSTXcyXk1oTXQEdDJWBn9mDAo=","MIXED_CONTENT":"UwVaBXciUU9rWXsGdDJaQnxjc113MmRNaGNwTXQxZE18TXBOdCFkBGhjdAV0MXxNfnB4QHciZ1h8Y3QHdyJkQmhjY193MmQEfwV4TWALeAVrc2NbdAx0TH5zfAZgMmNYa1prXGALZAg=","VIAFOURA_SITE_UUID":"VQUFB11UeAF/BVYCYBxaTXxjZ190InwFa2NwBXcyeEJoXWRPdzJkTGhdYAJ0C2NcfF18TXQMVgZ+c1VddzFsBmhNe150IXhMf11SBnRUbEx+c2tdd1RwTGhae190HFZMfE1/W3cMVkxoXXwFdwx0CA==","GOOGLE_CLIENT_ID":"Un9ZXlsLDANQWXtCWDFeA3xgZE9jInRCf3NwB3YicAV8c3xAYzJzXHxzYEB0VGxMf3NrW3RUY1h8YHxAdzJwBnxwfE90HH9ef2NVWmALbEJrY11bYyJ8AWtafE53VGwBfAVrW3Qie1x8WnROYyFvXXxwf1tgMWxNa2NjWmAyd1xrXXNaYwxwBWtwf1tjIXtYa11zXHcyd15rc3xNdiJ0QmgFe1x0InAFfGN3XGMyd19rc3RPdwx0B3xjaE9jMnNdfHNSQHdUeAR8Y1pPdAx0Bg==","AUTH0_BASE_URL":"Um9rWHchZ1t/b10CdBxaBGtzdE90ImwEa3N0AncxfAV8Y3AGdCJWBXxzYAV0MXBMaAV4BWMydARoBXtadCJzWH5zY110DH9YaGN4AndUYE1+c3QDdxx4T2gFaEBgMn9Zf2BkTmMLb1x8dgwK","CHARTBEAT_DOMAIN":"VQV/WmAxAF9UWl1PYy50A3xjWkB3DHQFf3BoB3ccdAV8c3BAdwx3WGtjUkB3HHRC","G_OPTIMIZE_CONTAINER_ID":"aFoIT3QLYAV/BUVGYDF8A3xNUk50MmdffHNWBWMMbAd/XWgGdiJ7X3xzWk5gEQgI","G_TAG_MANAGER_CONTAINER_ID":"aE1dT11UDAZoBQkHY1VgA3xNUgR0MnxCfF10BHQyf1x/Y3hNYBxvXHxNeAo=","SF_CLIENT_SECRET":"fGBBWloMXQd/BVoGdCF4A39NfAZjMnwEf3NWBmMyZ198cGQGdzJRXH9NeE53DHdYfHNgBnYifEJ/TVZOdwxsAXxaeAR3DHABfE1kBGAyfE98WnRPdBxgAXxddE92Intdf11kBXQcdAV/WmhAdBx4TH9zUgZ0MnBMf1pgTXcibAB/YHRAYyF/X3xjWkB3DHAHf2BgT2AyY118YGtfYyJkT3xzWgd2InAEfGN0QHYiZABrcGAGYDFjX39wdAo=","G_RECAPCHA_V3_KEY":"VFlzR1w+Z1l8WlVOWDJaTGhjf190MnRNaF1STnQifAd+c3wGdDJ0TH5zd1p0C2QFfGN8B3QMUk98XWQEdAtgTXxdc150InhPfmBnW2MMe1hoTXdcdzJ4T35zYEB0IXBNa117WnQxbEJ/XXgFYBxWTX8FZEB0InxPf0AMCg==","G_RECAPCHA_V2_KEY":"UF1ZT1pUcwFoBWNfXTF4A39jWgd3DHtdf3NwQHYidEJrY3RPYAtgQnxjYE90InAGfF18T3QLbEx8c2BPdAx7WWtjUkB3HHdYfAV0TXQMVgR8Wmtbdxx0QnxdUgZ0MnQGfHNgTmAxbE98TWgFdDJ0Qn9wf1t3HHQBfAVgCg==","GROWTHBOOK_CLIENT_KEY":"fnAIWnRUWk1QTXNHY1R8A3xzeE90HH9df2NoBmMiZE18XXwHdiJ4AHxjdAZjDGRCf3N4TnQMd118Y3wHdwtgTA==","SOPHI_HOSTNAME":"a39BBFoxe1tVcFYDdxxeA3xwdE9jDHAEf2BoB2AydEJ8cGRAdxxkB2hdYAdjMnBPa1poQGAyd1lrY2gK","HTL_SCRIPT":"aFljWVwMZ01VYH9eYAsFA3xjeE93DGQBfGBkBHcMc1x8c2RPYwxwTX9waE93MnAGfE1gBnQydAF/c1VadzJkTGtjcE90MmNca2BnW2ALbE9rY3hAdDJWTHxdcAd2InwHa2B7W2MLY158XWNaYyFgAXxdf193IWAAa2NkTXccf1h8c3ddYBx4TWtzY113VGBM","LIVEBLOG_WS_SERVER":"aE1/BVwxBER/cAQFWgsFA3xwYAZ3DHAFf2NSB3cid15/cGRAdDJ0AWtddE9gMnAFaF1oT2AMd1l8Y3RPYAxnXGtjWkB2Mntef2NwBmAcbE1rWmdbdiFgTw==","SOPHI_SCRIPT":"fn9wBnY+RVtTBFkEYyEFA39zVk90DHNdfHNwT2MyfE9/Y3wHdzJnXHxddAZ3HFFdfGBoQHQiZAF8c2hPdwxwBWtdd1pjMWABfF1oQHdUb11/cHtfdDFvXWtjYE50MWwBfE1zWncxb11oXVVbdAtzX39dfE13VGABa2NwTmMhb19rXXddYyJjX2tzdAV0VHAGa2BjWmMyeE18XWdcdwt7XmhNdAJ3IWdYaGNaCg==","STATS_WIDGET_CLIENT_ID":"UmAFTnRUAFh/b1kDWwteA3xzcEB0MmRNf2B8B3Yic15/YHhPdxxzX3xgYE9jInQAf2BgB2AyZEx8YHRPdyJnXnxzY1p2ImAE","_id":"73851370f09e81e9ff70c0687fb037744bde541370c66e3a909984807de2e7d3"}
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
After markets rattle, Trump once again punts on following through with threat on Iran power plantsIn his initial threat, he gave Tehran 48 hours to open up the Strait of Hormuz.
Read more »
Anker’s 160W Prime Charger can power three devices at once, and it’s $50 offAnker’s 160W Prime Charger is down to $99.99 for Amazon’s Big Spring Sale. The USB-C charger can power up three devices at once, including beefier laptops.
Read more »
Trump considers renaming Strait of Hormuz after either America or himself -- once he evicts IranToday's Video Headlines: 03/27/26
Read more »
Nob Hill Foods to shut Mountain View store, chop dozens of jobsNob Hill Foods will shut a South Bay supermarket and slash scores of jobs.
Read more »
Congressional Perks: Senate spending skyrockets by more than 40% in last few yearsSpending in U.S. senators' office accounts spiked by 43% since 2020, with big jumps in 2022.
Read more »
Leeds woman with cancer calls for screening to tackle sterotypesMaria Elliott was diagnosed with terminal lung cancer in 2022, but currently lives disease-free.
Read more »